Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...

In A Nutshell Three Brazilian supercentenarians survived COVID-19 in 2020 before vaccines existed, showing remarkably strong antibody responses that suggest exceptional immune resilience even at ages ...

Teclistamab and daratumumab combination achieved 100% MRD negativity and VGPR or better in all patients, with excellent tolerability and no severe CRS or ICANS. The trial's primary endpoint was VGPR ...

Even when immune memory cells form in the lung after influenza infection, insufficient dietary iron leaves them less able to mount a strong antiviral response, revealing how nutrition can shape ...

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted ...

Most women living with HIV achieved an immunologic response after 2 years of initiating antiretroviral therapy. A higher baseline HIV viral load increased the odds of an immunologic response in women ...

As we have learned multiple times in the past few centuries, pathogens have no respect for borders. Any local germ circulating in small outbreaks has the potential to suddenly make a global jump, ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused five clinical trials. Gilead also stressed that the hold does not impact any ...

1 Reference Laboratory of Health Program Fighting Against AIDS in Benin (LR/PSLS), Health Ministry of Benin, Cotonou, Benin. 2 Laboratory of Cell Biology, Physiology and Immunology, Department of ...